SynthesisWorld journal of urology2026
Salvage therapies for local recurrence of renal cell carcinoma: a systematic review and meta-analysis.
Synthesis in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to systematically summarize data on efficacy of local salvage therapies for local recurrence of renal cell carcinoma (RCC).
methodsWe searched MEDLINE, Embase, Web of Science, CENTRAL, and Google Scholar through 05/08/2026, for studies on local salvage therapies for local recurrence of RCC following radical nephrectomy, partial nephrectomy, or ablation (PROSPERO: CRD42024623099). Meta-analyses were conducted using random-effects models. Risk of bias (RoB) was assessed using ROBINS-I.
resultsForty-seven studies comprising 2039 patients were included (45 retrospective). Patients recurring after primary ablation predominantly presented with new renal masses, and were managed with repeat ablation (6 studies, n = 193) or salvage surgery (3 studies, n = 48), both yielding low recurrence rates. Local recurrences (M0) after primary partial nephrectomy (PN), most often in patients with pT1 disease, were treated with repeat PN, radical nephrectomy (RN), or ablation (15 studies, n = 562), with heterogeneous outcomes across modalities, ranging from low recurrence rates to predominantly distant metastatic failure. In contrast, recurrences after primary RN (12 studies, n = 564) occurred in a population with primarily locally advanced disease (pT3-4) and outcomes were notably worse, driven by distant progression. Four studies used radiotherapy in salvage setting, with heterogeneous methods and outcomes. Majority of studies were assessed moderate RoB, 16 studies assessed as serious, predominantly due to bias in participant selection.
conclusionEfficacy of local salvage therapies for RCC recurrence is influenced by the primary treatment and histopathological advancement of primary disease. Repeat ablation provides favorable outcomes, while recurrences after PN can be managed with repeat surgery or ablation, with heterogeneous results (from low recurrence rates to frequent distant metastases). Post-RN patients, often with initially advanced disease, have worse prognosis with approximately two-thirds experiencing progression by three years, primarily due to distant metastases. Overall, quality of evidence remains low. There is critical need for expert consensus on quality indicators for locally recurrent RCC care and for prospective registries with standardized outcome reporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.